A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
Status:
Terminated
Trial end date:
2020-12-22
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to characterize the single dose pharmacokinetic of
erdafitinib in participants with impaired hepatic function relative to participants with
normal hepatic function.